Navigation Links
GeoVax Labs Reports 2012 First Quarter Financial Results
Date:5/15/2012

icate superior protection when compared to similar viral challenge studies for competitive vaccine designs currently in human clinical trials. We are therefore very excited about the potential for our vaccine."

Dr. McNally continued, "On the financial side, we continue to benefit from NIH/HVTN support of our human clinical trials and we are seeking additional government support to fund our internal research and development activities to expand the use of our technology against strains (clades) of the HIV virus affecting other areas of the globe. From December 2011 to March 2012, we raised a total of $2.7 million in equity capital to bolster our cash reserves."

Comment on Gilead Science's Truvada® Prevention SubmissionDr. McNally also commented on the recent news related to an advisory panel's recommendation that the FDA approve Gilead Science's submission of their anti-viral medication, Truvada, for prevention of HIV. "While any positive step towards the control of this deadly disease is greatly welcomed, we must continue the search for safe, cost-effective measures to prevent HIV transmission. The high cost of oral medications, patient compliance, and risk of medical side effects clearly suggest the best solution still lies with a preventive vaccine. GeoVax's preventive vaccine is considered a leading candidate for the version of the virus prevalent in North and South America, and Europe."

Financial ReviewGeoVax reported a net loss for the three months ended March 31, 2012 of $730,513, or $0.04 per share, based on 16.7 million weighted average shares outstanding. For the three months ended March 31, 2011, the Company reported a loss of $606,282, or $0.04 per share, based on 15.7 million weighted average shares outstanding.

The Company reported revenues of $854,063 for the three months ended March 31, 2012, related to its Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the National Institutes
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. GeoVax Labs CEO Update Letter to Shareholders
2. GeoVax Labs First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine
3. GeoVax Phase 2a Clinical Trial Completes Enrollment
4. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
5. GeoVax Labs, Inc. Announces Second Quarter Financial Results
6. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
7. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
8. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
9. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
10. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
11. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Sigma-Aldrich Corporation (NASDAQ: ... Technology company, today announced the opening of its ... state-of-the-art Cell Culture Technical Center in Singapore.  Located ... customized support to meet customer needs, leveraging the ... new Technical Center will significantly enhance our ability ...
(Date:4/17/2015)... , April 17, 2015 TWi Pharmaceuticals, ... subsidiary, TWi Pharmaceuticals USA , has ... the United States.  It has been in close contact ... and expects to have its own label specialty generic ... in the U.S. pharma market. According to ...
(Date:4/16/2015)... , April 16, 2015 Mindray ... developer, manufacturer, and marketer of medical devices worldwide, ... Securities and Exchange Commission an Annual Report on Form ... year ended December 31, 2014. An electronic version of ... on Mindray,s investor relations website at  http://ir.mindray.com  or  ...
Breaking Medicine Technology:Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
... 14, 2011 Reportlinker.com announces that a new ... Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic title=,The 2011 Prostatic ... Test Volume, Sales ... Acid Phosphatase Testing Market: US, Europe, Japan ...
... Nov. 14, 2011 Reportlinker.com announces that a ... catalogue: Smart Infusion Pumps ... is one of the most common therapeutic procedures ... to receive. Yet the lack of standardization among ...
Cached Medicine Technology:The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 2The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 3The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 4The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 5Smart Infusion Pumps 2Smart Infusion Pumps 3
(Date:4/18/2015)... Carinsurancesavings.biz has released a new blog post ... during Spring. , Spring can be a great ... make sure they compare the newest policies before deciding ... more about Spring car insurance offers by reading the ... are becoming more and more popular. Many insurance brokerage ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Review of ... hosting a ‘Strategies for Success’ program for cataract surgeons ... meeting in San Diego, where eye surgeon Jeffrey L. ... this invitation-only event. Dr. Martin is the Managing Partner ... of Ophthalmology chose Dr. Martin to lead this year’s ...
(Date:4/18/2015)... Patients who undergo radiation for a ... in life, but the disease is likely to differ ... to radiation. Surviving Mesothelioma has just posted the details ... here to read it now. , Scientists from ... 45 patients who had both a hematologic cancer (like ...
(Date:4/18/2015)... NY (PRWEB) April 18, 2015 On April ... Security Threat Report , which they say, “exposes a tactical ... many new malware variants were introduced in 2014 - almost ... for Zero Day threats to be identified and patched by ... is abundantly clear that doing business in a digital world ...
(Date:4/18/2015)... Canada (PRWEB) April 18, 2015 French ... emotions on food choices when he uttered, “Tell me ... you are.” Using food to cope with stress or ... by Queendom.com indicates otherwise. Data collected from ... genders fall victim to emotional eating, but for different ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6
... regimen popular in 1980s doesn,t really lengthen life , , ... only a minimal effect on survival in breast cancer ... pretty clearly established that [high-dose chemotherapy] is a false ... Division of Quantitative Sciences at the University of Texas ...
... is a three-day multidisciplinary meeting that will serve as ... the prevention, screening and treatment of gastrointestinal cancers. More ... years Symposium which will feature nearly 600 scientific abstracts. ... 27, 2008, WHERE:, Orlando World Center Marriott , 8701 ...
... at the Universities of Nottingham and Leicester are collaborating ... image and quantify the air spaces inside the lungs ... to a link between childhood disease and later degenerative ... the world which have access to this particular magnetic ...
... Boston, MAMichael F. Holick, PhD, MD, was recently awarded ... Society of Endocrinology and Metabolism (CSEM). Holick, an ... received the award for decades of pioneering work that ... wide variety of chronic health conditions. , ...
... at Henry Ford Hospital on the use of a drug ... and aggressive type of brain cancer, has yielded results that ... II study focused on patients with glioblastoma multiforme (GBM), whose ... revealed that more than a third who were treated with ...
... them from being attacked by the female immune system could ... the human body, according to new research published on 14 ... in the Journal of Biological Chemistry, analysed these markers which ... sperm are not dangerous pathogens, and therefore should not be ...
Cached Medicine News:Health News:High-Dose Chemo Provides Little Benefit to Breast Cancer Patients 2Health News:High-Dose Chemo Provides Little Benefit to Breast Cancer Patients 3Health News:New technique reveals insights into lung disease 2Health News:Boston University Medical Center researcher honored 2Health News:Drug study for brain cancer shows promising results 2Health News:Sperm's immune-protection properties could provide link to how cancers spread 2
... Tissue Anchor 3 mm is a resorbable repair ... using sutures. The resorbable repair device is implanted ... is used to attach soft tissue. The suture ... from glycolide and lactide colored with D&C violet ...
Sutureless Harpoon Tip...
... anchor is generally utilized when a surgeon would ... soft tissue, or seat the anchor below the ... 4.4mm anchor is the same as what comes ... a longer, calibrated shaft to easier gauge anchor ...
The MINI-TAG™ instrument systems are indicated for ulnar collateral ligament repair, scapholunate dissolution, flexor avulsions, and carpometa-carpal arthroplasty....
Medicine Products: